RYTM Announces FDA Approval of IMCIVREE for Acquired HO, -18.4% BMI Reduction in Phase 3, Conference Call 7PM ET
Rhythm Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $87.87
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS